Prognostic impact of genetic subgroups and development of gene classifiers for response, PFS and OS in multiple myeloma patients treated with bortezomib or conventional agents in HOVON65/GMMG-HD4 trial

This article has no abstract
Epistemonikos ID: 383e4360028565b416283201c46cd2f44c49e3c3
First added on: Feb 05, 2025